泽璟制药注射用人促甲状腺素β获批上市

Core Viewpoint - Zaiqiang Pharmaceutical has received approval from the National Medical Products Administration for its innovative drug, injection human thyroid-stimulating hormone beta, marking a significant advancement in the treatment of differentiated thyroid cancer [1] Group 1: Company Announcement - Zaiqiang Pharmaceutical announced the approval of its new drug application for injection human thyroid-stimulating hormone beta, previously known as injection recombinant human thyroid-stimulating hormone [1] - The approved indication is for use in the collaborative diagnosis of patients with differentiated thyroid cancer following total or near-total thyroidectomy, facilitating serum thyroglobulin (Tg) testing, with or without radioactive iodine (131I) whole-body scan (WBS) [1] - This product is the first of its kind in China approved for precise assessment post-surgery for differentiated thyroid cancer [1]